ESMO Congress 2025, LBA66) showed a highly significant DFS benefit (HR 0.24, 95% CI, 0.13-0.45 and HR 0.20, 95% CI, 0.11-0.38, respectively).
← all excerpts
<i>ROS1</i>-positive non-small cell lung cancer: from genomics to treatment decisions.
1
—
—